Mannkind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

6.08USD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$6.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,853,256
52-wk High
$11.48
52-wk Low
$3.80

MNKD.OQ

Chart for MNKD.OQ

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s approved product, AFREZZA, is inhaled insulin that was approved by the United States Food and Drug Administration (FDA) on June 27, 2014.

Overall

Beta: 1.20
Market Cap (Mil.): $2,446.48
Shares Outstanding (Mil.): 402.38
Dividend: --
Yield (%): --

Financials

  MNKD.OQ Industry Sector
P/E (TTM): -- 170.49 34.41
EPS (TTM): -0.66 -- --
ROI: -732.85 -1.91 17.37
ROE: -- -7.10 18.18
Search Stocks

US STOCKS-MannKind, Magnum Hunter among premarket actives

NEW YORK, Sept 25 - MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product.

25 Sep 2014

US STOCKS-Wall St up for second straight session in broad rally

* Indexes up: Dow 0.4 pct, S&P 0.6 pct, Nasdaq 1 pct (Updates to midday trading)

11 Aug 2014

US STOCKS-Wall St up for 2nd day as Ukraine tensions ease

* Indexes up: Dow 0.3 pct, S&P 0.5 pct, Nasdaq 0.6 pct (Updates to market open, adds analyst comment)

11 Aug 2014

US STOCKS-Futures higher as Ukraine tensions ease

NEW YORK, Aug 11 - U.S. stock index futures were higher on Monday, indicating that Friday's sharp rally could continue as it appeared less likely that the tense situation between Russia and Ukraine would escalate.

11 Aug 2014

UPDATE 2-Sanofi bets on inhaled insulin with MannKind deal

* MannKind gets $150 mln upfront, up to $775 mln in milestones

11 Aug 2014

REFILE-UPDATE 1-Sanofi bets on inhaled insulin with up to $925 mln MannKind deal

* MannKind gets $150 mln upfront, up to $775 mln in milestones

11 Aug 2014

Sanofi, MannKind agree licensing deal for Afrezza insulin

PARIS, Aug 11 - French drugmaker Sanofi and MannKind Corp have agreed a worldwide licensing deal to develop and market inhaled insulin therapy Afrezza for adults with diabetes.

11 Aug 2014

US STOCKS-S&P 500, Nasdaq set for 6th straight quarter of gains

* Dow down 0.1 percent; S&P 500 flat; Nasdaq up 0.3 percent (Updates with GM shares; updates prices)

30 Jun 2014

US STOCKS-S&P 500, Nasdaq set for sixth straight quarter of gains

* Dow down 0.1 pct; S&P 500 up 0.1 pct; Nasdaq up 0.4 pct (Updates to early afternoon)

30 Jun 2014

US STOCKS-Wall St little changed, set to end quarter higher

* Indexes: Dow flat, S&P 500 up 0.1 pct, Nasdaq up 0.2 pct (Updates to morning trading, adds comment)

30 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks